Jefferies flags disappointing Phase 2 eye-drop results for KHK4951
Jefferies says Kyowa Kirin’s latest Phase 2 clinical data for ophthalmology eye drops candidate KHK4951 is disappointing, materially weakening a key pipeline opportunity.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.